Vium
The AI engine Fit Assessment
BetaVium leverages machine learning to discover patterns and identify biomarkers, facilitating the advancement of new therapeutics in preclinical research.
Blurb
Vium is a biotechnology company that develops digital biomarkers to transform preclinical research and animal welfare.
HQ Location
United States
Founded
2013
Employees
51 - 200
Total funding raised
$53.94M
Last Funding Event
Acquired by Recursion Pharmaceuticals, July 2020
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Biomarker Identification
Provider of digital biomarkers intended to assist in pre-clinical drug research. The company's biomarkers are derived from artificial intelligence, machine learning and sensor technology and assists in accelerating the pre-clinical drug discovery and development pipeline, enabling researchers and drug developers to obtain improved insights into disease progression and take better decisions on which compounds should be advanced to the clinic.